D Agrawal1, Z F Udwadia, C Rodriguez, A Mehta. 1. Department of Respiratory Medicine, P D Hinduja National Hospital and Medical Research Centre, Mumbai, India. dipiagr@hotmail.com
Abstract
SETTING: Tertiary referral centre, private hospital, Mumbai, India. OBJECTIVE: To analyse the incidence of fluoroquinolone (FQ) resistant Mycobacterium tuberculosis (TB) in our laboratory from 1995 to 2004. DESIGN: Retrospective review and analysis of the drug susceptibility test records of all M. tuberculosis culture-positive samples from our Microbiology Department from 1995 to 2004. RESULTS: FQ resistance has increased exponentially in our laboratory, from 3% in 1996 to 35% in 2004. The incidence of multidrug-resistant tuberculosis has also increased during the same period, from 33% in 1995 to 56% in 2004. CONCLUSION: The incidence of FQ-resistant M. tuberculosis is gradually increasing to alarming levels. This may be due to widespread use of this vital group of drugs in the treatment of community-acquired infections. We urge that these broad spectrum antibiotics be used judiciously, and ideally be reserved for treatment of resistant TB in TB-endemic areas.
SETTING: Tertiary referral centre, private hospital, Mumbai, India. OBJECTIVE: To analyse the incidence of fluoroquinolone (FQ) resistant Mycobacterium tuberculosis (TB) in our laboratory from 1995 to 2004. DESIGN: Retrospective review and analysis of the drug susceptibility test records of all M. tuberculosis culture-positive samples from our Microbiology Department from 1995 to 2004. RESULTS:FQ resistance has increased exponentially in our laboratory, from 3% in 1996 to 35% in 2004. The incidence of multidrug-resistant tuberculosis has also increased during the same period, from 33% in 1995 to 56% in 2004. CONCLUSION: The incidence of FQ-resistant M. tuberculosis is gradually increasing to alarming levels. This may be due to widespread use of this vital group of drugs in the treatment of community-acquired infections. We urge that these broad spectrum antibiotics be used judiciously, and ideally be reserved for treatment of resistant TB in TB-endemic areas.
Authors: Rokeya Tasneen; Si-Yang Li; Charles A Peloquin; Dinesh Taylor; Kathy N Williams; Koen Andries; Khisimuzi E Mdluli; Eric L Nuermberger Journal: Antimicrob Agents Chemother Date: 2011-09-19 Impact factor: 5.191
Authors: T Tsukatani; H Suenaga; M Shiga; T Ikegami; M Ishiyama; T Ezoe; K Matsumoto Journal: Eur J Clin Microbiol Infect Dis Date: 2015-07-15 Impact factor: 3.267
Authors: Kathy Williams; Austin Minkowski; Opokua Amoabeng; Charles A Peloquin; Dinesh Taylor; Koen Andries; Robert S Wallis; Khisimuzi E Mdluli; Eric L Nuermberger Journal: Antimicrob Agents Chemother Date: 2012-04-02 Impact factor: 5.191